^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Purinergic receptor P2Y12 inhibitor

Related drugs:
7d
CAPTIVA: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (clinicaltrials.gov)
P3, N=1683, Active, not recruiting, University of Florida | Trial completion date: May 2028 --> Jan 2027 | Trial primary completion date: May 2028 --> Jan 2027
Trial completion date • Trial primary completion date
9d
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials (clinicaltrials.gov)
P=N/A, N=3710, Active, not recruiting, Nanjing First Hospital, Nanjing Medical University | Trial completion date: Dec 2025 --> Oct 2026
Trial completion date
|
aspirin
10d
PCI-GULF: PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (clinicaltrials.gov)
P=N/A, N=654, Not yet recruiting, Nanjing First Hospital, Nanjing Medical University | Initiation date: Jan 2026 --> Dec 2026
Trial initiation date
17d
New P3 trial
17d
STOP-IMH (2024-517783-37-00)
P4, N=200, Recruiting, Radboud universitair medisch centrum Stichting | Not yet recruiting --> Recruiting
Enrollment open
20d
New P4 trial
23d
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE) (clinicaltrials.gov)
P=N/A, N=37, Completed, Rennes University Hospital | Recruiting --> Completed | N=100 --> 37
Trial completion • Enrollment change
1m
TIMO: Ticagrelor Monotherapy After Stenting (clinicaltrials.gov)
P2, N=200, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jun 2025
Trial completion • Trial completion date
1m
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. (PubMed, Biochem Pharmacol)
Ticagrelor synergistically enhanced the cytotoxicity of Adriamycin (Adr) and Paclitaxel (PTX) in MCF-7/Adr and MCF-7/PTX cells, respectively. In conclusion, Ticagrelor reverses breast cancer MDR by concurrently inhibiting PI3K/AKT/mTOR signaling, downregulating ABCB1 expression and function. Our findings highlight the potential of Ticagrelor as a dual-acting agent that not only targets tumor metastasis but also overcomes chemoresistance, providing a new strategic direction for combination therapy in refractory breast cancer.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1)
|
paclitaxel • doxorubicin hydrochloride
1m
Enrollment open
1m
TAILOR BLEED: Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (clinicaltrials.gov)
P4, N=90, Recruiting, University of Florida | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Dec 2026
Trial completion date • Trial primary completion date
2ms
EPIDAURUS: Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI (clinicaltrials.gov)
P4, N=2334, Completed, Ludwig-Maximilians - University of Munich | Active, not recruiting --> Completed
Trial completion